In his capacity as Chair of Medicinal Cannabis Industry Australia, Cann Group CEO Peter Crock recently met with senior bureaucrats from the Therapeutic Goods Administration and the Office of Drug Control, including Prof John Skerritt, Deputy Secretary, Health Products Regulation Group, TGA. The meeting covered the upcoming changes to import quality standards, ways to further streamline narcotic drug licenses and permits, and the potential for more detailed reporting of industry performance data. The following week, Mr. Crock also led MCIA's meeting with the Hon. Ged Kearney, Assistant Minister for Health and Aged Care.
L-R: MCIA Chair and Cann Group CEO Peter Crock meets the Hon. Ged Kearney and Patty Holmes, a specialist in the medicinal cannabis industry
While Cann Group engages directly with governments and regulators to address company-specific concerns, advocacy is most effective when coordinated through an association. This is why Cann Group has invested time and effort into being involved in forming and leading MCIA and building trusted relationships with the government that allow the MCIA to speak with an industry voice and authority on issues affecting the entire medicinal cannabis ecosystem.
Members attend the MCIA board meeting in Canberra in early July, which included a Zoom and in-person session with Office of Drug Control (ODC) and Therapeutic Goods Administration (TGA) representatives, including Danielle Chiffley and John Skerritt
"We are particularly focused on ensuring that imported medicinal cannabis products are held to the same high level of quality compliance as Australian-made products. This is essential for protecting the reputation of the industry and ensuring that prescribers and patients have confidence in the regulatory framework."
For more information: